Sanofi-Aventis Recherche & Developpement — Sponsor Intelligence | 116 EU Trials

Filter these 116 trials by condition, phase, country and more.

Open in Search →

116 Registered trials

45 Recruiting

66 Completed trials

25 Countries active

78 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 43 Phase II/III: 4 Phase II: 41 Phase I/II: 6 Phase IV: 2 Phase I: 6 Phase I (Other): 8 Phase I (FiH): 4 Other: 1 Other: 1

Oversight events:

5 temporary halts 3 unexpected events 1 corrective measure across 6 trials

View oversight register →

100%

66 of 66 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Dermatitis atopic 9 Chronic obstructive pulmonary disease 7 Multiple sclerosis 6 Plasma cell myeloma refractory 6 Asthma 6 Chronic rhinosinusitis with nasal polyps 5 Colitis ulcerative 5 Crohn´s disease 4 Plasma cell myeloma 3 Autoimmune haemolytic anaemia 2 Clinical trial participant 2 Neurodermatitis 2

Top IMPs

ISATUXIMAB 10 AMLITELIMAB 9 DEXAMETHASONE 9 ITEPEKIMAB 9 FREXALIMAB 6 LUNSEKIMIG 6 DUPILUMAB 5 RILIPRUBART 5 RILZABRUTINIB 5 DEXAMETHASONE SODIUM PHOSPHATE PH. EUR. 4 DUVAKITUG 4 BALINATUNFIB 3

All trials

116 total

Sarilumab efficacy and safety in adults with early polymyalgia rheumatica Pending

2024-511296-15-00 Phase III 9 countries PREDNISONE; SARILUMAB
Efficacy, safety, and tolerability study of lunsekimig compared with placebo in adult participants with inadequately controlled chronic obst… Pending

2024-518016-39-00 Phase II/III 9 countries LUNSEKIMIG
Efficacy, safety, and tolerability study of lunsekimig compared with placebo in adult participants with inadequately controlled chronic obst… Pending

2024-518213-25-00 Phase II/III 6 countries LUNSEKIMIG
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending

2025-521037-86-00 Phase III 15 countries DUVAKITUG
A Study to Access Activity and Safety with SAR445399 Compared with Placebo in Participants Aged 18 to 80 Years of Age with Non-Cystic Fibros… Pending

2025-523403-29-00 Phase II 5 countries SAR445399
A Phase 1 first-in-human study to evaluate SAR448272 in adult participants Pending

2026-526014-87-00 Phase I 1 country
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti… Recruiting

2025-521038-27-00 Phase III 15 countries DUVAKITUG
An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr… Recruiting

2025-522983-33-00 Phase III 15 countries ITEPEKIMAB
A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative co… Recruiting

2025-522511-42-00 Phase II 14 countries BALINATUNFIB
Long-term safety and efficacy evaluation of lunsekimig (SAR443765) in adult participants with moderate-to-severe asthma. Recruiting

2025-522896-27-00 Phase II 9 countries
A study to investigate the efficacy and safety of frexalimab versus tacrolimus in adults undergoing kidney transplantation Recruiting

2025-521521-33-00 Phase II/III 12 countries FREXALIMAB; TACROLIMUS
A study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12 years with hemophilia A … Recruiting

2025-521858-42-00 Phase III 7 countries FITUSIRAN
A study of belumosudil in children with chronic graft versus host disease (schoolROCK). Recruiting

2024-511508-18-00 Phase I/II 6 countries BELUMOSUDIL MESILATE
A study to test how well an oral medication called rilzabrutinib works and how safe it is for adults with immune thrombocytopenia (ITP) who … Recruiting

2025-522070-36-00 Phase III 8 countries RILZABRUTINIB
A study to investigate airway inflammation with dupilumab subcutaneously in participants aged ≥40 to ≤85 years with chronic obstructive pulm… Recruiting

2025-521268-37-00 Phase IV 10 countries DUPILUMAB; SALBUTAMOL
The efficacy and safety of rilzabrutinib in participants aged 10 to 65 years with sickle-cell disease Recruiting

2024-518645-17-00 Phase III 7 countries RILZABRUTINIB
Long-term safety and efficacy study of riliprubart in participants with CIDP Recruiting

2024-517032-22-00 Phase III 14 countries RILIPRUBART
A study to investigate improvement in pruritus of Lichen Simplex Chronicus with dupilumab injections compared with placebo in male and femal… Recruiting

2024-514737-37-00 Phase III 8 countries DUPILUMAB
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Recruiting

2023-504358-36-00 Phase III 18 countries
A study to evaluate the efficacy and safety of subcutaneous amlitelimab on background topical corticosteroids therapy in participants aged 1… Recruiting

2023-508099-12-00 Phase III 7 countries AMLITELIMAB
Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Phase II/III 13 countries AMLITELIMAB
BIVV020 (SAR445088) in prevention and treatment of antibody-mediated rejection (AMR) Recruiting

2023-509936-25-00 Phase II 5 countries RILIPRUBART
A study to evaluate the effect of venglustat tablets on left ventricular mass index in male and female adult participants with Fabry disease Recruiting

2023-509715-91-00 Phase III 11 countries AGALSIDASE ALFA; AGALSIDASE BETA; MIGALASTAT; VENGLUSTAT
A study to investigate a potential effect of rilzabrutinib (SAR444671) on ethinylestradiol and levonorgestrel from combined oral contracepti… Recruiting

2026-525350-11-00 Phase I (Other) 1 country

Showing 1–24 of 116 trials

← All sponsors A–Z